Rezolute (RZLT) POS AM 14 Oct 16 Prospectus update (post-effective amendment) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jun. 30, 2016
Document Information [Line Items]
Document Type	POS AM
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Entity Registrant Name	AntriaBio, Inc.
Entity Central Index Key	1,509,261
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ANTB

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Current assets
Cash	$ 4,062,013	$ 5,278,706
Restricted cash	0	450,167
Other current assets	430,094	387,511
Total current assets	4,492,107	6,116,384
Non-current assets
Fixed assets, net	5,984,670	4,524,912
Intangible assets, net	51,614	58,906
Deposit	375,000	563,000
Total non-current assets	6,411,284	5,146,818
Total Assets	10,903,391	11,263,202
Current liabilities:
Accounts payable and accrued expenses	1,500,650	1,408,399
Convertible notes payable	60,000	60,000
Deferred lease liability, current portion	119,688	98,671
Lease payable, current portion	23,128	93,852
Interest payable	15,079	13,079
Warrant derivative liability	11,955	31,777
Total current liabilities	1,730,500	1,705,778
Non-current liabilities:
Deferred lease liability, less current portion	400,038	480,490
Lease payable, less current portion	0	23,127
Total non-current liabilities	400,038	503,617
Total Liabilities	2,130,538	2,209,395
Commitments and Contingencies (Note 13)
Stockholders' equity:
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 35,110,916 and 24,338,219 shares issued and outstanding, June 30, 2016 and 2015, respectively	35,114	24,341
Additional paid-in capital	52,782,569	38,138,754
Accumulated deficit	(44,044,830)	(29,109,288)
Total stockholders' equity	8,772,853	9,053,807
Total Liabilities and Stockholders' Equity	$ 10,903,391	$ 11,263,202

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2016	Jun. 30, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	35,110,916	24,338,219
Common stock, shares outstanding	35,110,916	24,338,219

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Research and development
Compensation and benefits	$ 4,374,763	$ 2,068,236
Consultants and outside costs	1,317,465	742,229
Material manufacturing costs	2,414,708	1,355,882
Facilities and other costs	1,341,452	534,862
Research and development	9,448,388	4,701,209
General and administrative
Consulting fees	0	349,633
Compensation and benefits	3,891,916	3,778,791
Professional fees	441,978	526,257
Investor relations	259,351	523,345
General and administrative	909,657	818,647
General and Administrative	5,502,902	5,996,673
Total operating expenses	14,951,290	10,697,882
Loss from operations	(14,951,290)	(10,697,882)
Other income (expense)
Interest income	965	4,970
Interest expense	(5,039)	(6,729)
Derivative income (loss)	19,822	(662,723)
Total other income (expense)	15,748	(664,482)
Net loss	(14,935,542)	(11,362,364)
Cummulative Preferred Stock Dividend	(5,974,385)	0
Net Loss attributable to common stock	$ (20,909,927)	$ (11,362,364)
Net loss per common share - basic and diluted	$ (0.84)	$ (0.54)
Weighted average number of common shares outstanding - basic and diluted	24,773,213	20,950,191

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Jun. 30, 2014	$ 6,406,731	$ 18,092	$ 24,135,563	$ (17,746,924)
Balance (in shares) at Jun. 30, 2014		18,091,792
Stock-based compensation	2,846,828	$ 0	2,846,828	0
Issuance of common stock for services	368,419	$ 207	368,212	0
Issuance of common stock for services (in shares)		205,506
Fair value of warrants issued	6,026,070	$ 0	6,026,070	0
Issuance of common stock	4,768,123	$ 6,042	4,762,081	0
Issuance of common stock (in shares)		6,040,921
Net loss	(11,362,364)	$ 0	0	(11,362,364)
Balance at Jun. 30, 2015	9,053,807	$ 24,341	38,138,754	(29,109,288)
Balance (in shares) at Jun. 30, 2015		24,338,219
Stock-based compensation	3,761,837	$ 0	3,761,837	0
Fair value of warrants issued	5,523,706	0	5,523,706	0
Dividends on Series A Preferred Stock	(5,974,385)	0	(5,974,385)	0
Conversion of Series A Preferred Stock into common stock	5,307,909	$ 5,897	5,302,012	0
Conversion of Series A Preferred Stock into common stock (in shares)		5,897,677
Exchange on Series A Preferred Stock	2,929,084	$ 0	2,929,084	0
Issuance of common stock	3,106,437	$ 4,876	3,101,561	0
Issuance of common stock (in shares)		4,875,020
Net loss	(14,935,542)	$ 0	0	(14,935,542)
Balance at Jun. 30, 2016	$ 8,772,853	$ 35,114	$ 52,782,569	$ (44,044,830)
Balance (in shares) at Jun. 30, 2016		35,110,916

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Common Stock [Member]
Payments of stock issuance costs	$ 1,053,748	$ 3,144,479

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (14,935,542)	$ (11,362,364)
Amortization of intangible asset	7,292	5,255
Depreciation expense	743,962	128,870
Stock-based compensation expense	3,761,837	2,846,828
Stock issued for services	0	298,419
Warrant expense	72,972	93,564
Derivative (gains) losses	(19,822)	662,723
Forgiveness of accounts payable and accrued expenses - related party	0	(132,339)
Changes in operating assets and liabilities:
(Increase) decrease in other assets	(42,083)	172,514
Increase in accounts payable and accrued expenses	26,370	436,688
(Decrease) in accounts payable and accrued expenses - related party	0	(264,716)
Increase in interest payable	2,000	2,000
(Decrease) increase in deferred lease liability	(105,484)	33,664
Net Cash Used In Operating Activities	(10,488,498)	(7,078,894)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(2,091,790)	(3,107,957)
Acquisition of intangibles	0	(55,000)
Return of security deposit	187,500	0
Decrease (increase) in restricted cash	450,167	(450,167)
Net Cash Used In Investing Activities	(1,454,123)	(3,613,124)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on lease payable	(93,851)	(67,898)
Proceeds from issuance of equity financing	5,362,521	11,175,656
Proceeds from issuance of preferred stock	6,347,615	0
Payment of placement agent compensation and issuance costs	(890,357)	(1,071,568)
Net Cash Provided By Financing Activities	10,725,928	10,036,190
Net decrease in cash	(1,216,693)	(655,828)
Cash - Beginning of Year	5,278,706	5,934,534
Cash - End of Year	4,062,013	5,278,706
Cash Paid During the Period for:
Taxes	0	0
Interest	0	0
Non-Cash Transactions:
Conversion of preferred stock to common stock	5,923,200	0
Deemed dividend on conversion of preferred stock	5,811,708	0
Series A Preferred Stock dividend paid in stock	162,677	0
Warrant derivative liability reclassified as equity	0	2,342,039
Warrant value recorded as issuance costs	750,484	1,745,498
Lease Payable
Non-Cash Transactions:
Fixed assets acquired	0	184,877
Tenant Improvements
Non-Cash Transactions:
Fixed assets acquired	46,049	511,616
Accounts payable and Accrued expenses
Non-Cash Transactions:
Fixed assets acquired	$ 65,881	$ 511,400

Nature of Operations

Nature of Operations	12 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Operation [Text Block]	Note 1 Nature of Operations These financial statements represent the consolidated financial statements of AntriaBio, Inc. (“AntriaBio”), formerly known as Fits My Style, Inc., and its wholly owned operating subsidiary, AntriaBio Delaware, Inc. (“Antria Delaware”). AntriaBio and Antria Delaware are collectively referred to herein as the “Company”.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 Summary of Significant Accounting Policies The principal accounting policies applied in the preparation of these financial statements are set out below. – 11 7,292 General and Administrative Expenses Impairment of Long-Lived Assets The Company follows ASC 740 (formerly known as FIN No. 48, Accounting for Uncertainty in Income Taxes An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Although there were common stock equivalents of 33,462,014 21,556,142 – Fair Value Measurements and Disclosures ⋅ Level 1: Quoted prices for identical assets and liabilities in active markets; ⋅ Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ⋅ Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, restricted cash, accounts payable, and convertible notes payable approximated fair value as of June 30, 2016 and 2015 due to the relatively short maturity of the respective instruments. The warrant derivative liability recorded as of June 30, 2016 and 2015 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value instrument with the entire change in the balance recorded through earnings. See significant assumptions in Note 11. Balance as of June 30, 2015 $ (31,777) Total unrealized gains (losses): Included in earnings 19,822 Balance as of June 30, 2016 $ (11,955) Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items (Subtopic 225-20) In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes, In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09. Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. –

Going Concern

Going Concern	12 Months Ended
	Jun. 30, 2016
Going Concern [Abstract]
Going Concern Disclosure [Text Block]	Note 3 Going Concern As reflected in the accompanying financial statements, the Company has a net loss of $ 14,935,542 10,488,498 8,772,853 44,044,830 The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than one year. The ability of the Company to continue its operations is dependent on Management's plans, which include continuing to raise equity based financing. There is no assurance that the Company will be successful in accomplishing this objective. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Critical Accounting Estimates a

Critical Accounting Estimates and Judgments	12 Months Ended
	Jun. 30, 2016
Critical Accounting Estimates And Judgments [Abstract]
Critical Accounting Estimates And Judgments [Text Block]	Note 4 Critical Accounting Estimates and Judgments Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year include: Useful Life and Impairment of Depreciable Assets Share-based Payments and Warrants Warrant Derivative Liability Contingent Liabilities Income Taxes

Acquisition of Assets

Acquisition of Assets	12 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Note 5 Acquisition of Assets On January 30, 2013, the Company closed on an asset purchase agreement with the Chapter 7 Estate of PR Pharmaceuticals, Inc. (PRP). Pursuant to the agreement, the Company has acquired certain tangible and intangible assets in exchange for $ 400,000 100,000 44,000,000 On November 6, 2014, the Company closed on an asset purchase agreement with the Chapter 7 Estate of PRP in which the Company acquired its contingent consideration payments in exchange for $ 55,000

Fixed Assets

Fixed Assets	12 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 6 Fixed Assets Useful Life June 30, 2016 June 30, 2015 Furniture and fixtures 5 - 7 years $ 62,730 $ 55,330 Lab equipment 3 - 15 years 3,585,590 889,672 Lab equipment (not yet placed in service) 3 - 15 years 4,025 1,371,440 Leasehold Improvements 3 - 7 years 3,211,575 29,296 Construction in process - - 2,315,803 6,863,920 4,661,541 Less: accumulated depreciation and amortization (879,250) (136,629) $ 5,984,670 $ 4,524,912 The fixed assets as of June 30, 2015 included $ 2,315,803 743,962 128,870

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 7 Related Party Transactions During the year ended June 30, 2016, there were no related party expenses. During the year ended June 30, 2015, the Company incurred consulting expenses of $ 99,000 132,339 On February 29, 2016, we entered into a Strategic Collaboration and License Agreement (“Collaboration Agreement”) with pH Pharma Co., Ltd. (“PH”). Dr. Huh, an officer and Director of the Company is also the CEO of PH and a majority owner. Pursuant to the Collaboration Agreement, the Company conditionally granted PH an exclusive, transferable, license under AB101 patents, patent applications and all other relevant Company intellectual property to manufacture and or offer for sale the Company’s lead product candidate, AB101, in Korea, Cambodia, Laos, Myanmar, Thailand, Malaysia, Singapore and Vietnam (the “License”). The License shall only become effective when PH has purchased a minimum of $ 8 2 License to become effective, PH must purchase at least $6 million of the Company’s common stock in one or more private placement transactions at prices to be negotiated in good faith by the parties based on commercially reasonable terms. On July 1, 2016, the Company and PH entered into a Master Services Agreement in which PH will perform business development services in Korea for the Company at a fee of $ 10,350

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 8 Convertible Notes Payable From 2010 to January 2014, the Company issued several series of convertible promissory notes for which principal and interest were due between six months and two years after issuance. The convertible notes allowed investors to convert their shares into common stock at the time of certain qualifying events with some of the notes also issuing warrants at the time of conversion. On March 31, 2014, the Company closed on an equity transaction which qualified as a “qualified financing.” As such the $ 2,703,000 2,186,838 4,275,172 3,111,126 As of June 30, 2016 and 2015, the convertible notes outstanding balance was $ 60,000 60,000 8

Series A Convertible Preferred

Series A Convertible Preferred Stock	12 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Series A Convertible Preferred Stock [Text Block]	Note 9 Series A Convertible Preferred Stock On December 7, 2015, the Board of Directors authorized fifteen million shares of Series A Convertible Preferred Stock (“Series A Stock”). The Series A Stock had a conversion feature at the option of the holder that could be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also had a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Company’s listing to NASDAQ Stockmarket or the NYSE MKT and the Company’s common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stock’s conversion price was subject to weighted average anti-dilution protection, as defined, and was subject to adjustments for stock splits, dividends, and similar events. 6 On December 10, 2015, the Company closed an initial offering of its Series A Stock with an offering price of $ 1.95 1,025,699 1,803,548 105,715 90,852 1.95 1,716,487 2,956,975 231,214 159,311 1.95 512,820 1,000,000 22,846 Through June 24, 2016, the Company declared and issued 71,708 On June 24, 2016, the Company and the stockholders of the Series A Preferred Stock consented to convert all of the shares of Series A Preferred Stock into common stock. The conversion occurred at a conversion price of $ 1.95 Series A stockholder to exchange the Conversion Shares into shares of common stock and related warrants equal to the Series A Preferred Stock purchase price plus accrued dividends at an exchange rate of $1.10 per Exchange Share and related Exchange Warrant. 3,326,714 5,897,677 5,811,700 2,929,084

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	12 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 10 Stockholders’ Equity (Deficit) Common Stock - 200,000,000 0.001 a. One non-cumulative vote for each share held of record on all matters submitted to a vote of the stockholders; b. To participate equally and to receive any and all such dividends as may be declared by the Board of Directors out of funds legally available therefore; and c. To participate pro rata in any distribution of assets available for distribution upon liquidation. Stockholders have no pre-emptive rights to acquire additional shares of common stock or any other securities. Common shares are not subject to redemption and carry no subscription or conversion rights. Preferred Stock 20,000,000 0.001 On March 31, 2014, the Company entered into a services agreement whereby the Company receives assistance with investor relations relating to digital strategy, website and investor materials, market awareness and other services. The compensation for these services was up to 500,000 166,668 296,669 During 2015, the Company completed two private placement transactions in which the Company issued 6,040,921 2.50 36 10.1 1,071,568 2,072,911 37,838 70,000 During 2016, the Company entered into a private placement transaction in which the Company issued 4,875,020 1.65 60 4.8 553,428 500,321 On July 29, 2016, the Company completed an additional close of the private placement transaction in which the Company issued 418,182 460 The Company has not declared or paid any dividends or returned any capital to common stock stockholders as of June 30, 2016 and 2015.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Compensation [Text Block]	Note 11 Stock-Based Compensation Options 1,500,000 4.50 8,334 4.50 On March 26, 2014, the Company adopted the AntriaBio, Inc. 2014 Stock and Incentive Plan which allows the Company to issue up to 3,750,000 2,835,000 460,000 1.29 3.44 On February 23, 2015, the Company adopted the AntriaBio, Inc. 2015 Non Qualified Stock Option Plan which allows the Company to issue up to 6,850,000 4,112,000 285,000 1.00 2.06 4 AntriaBio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of a peer company. Due to the small number of option holders and all options being to officers, directors, or high level employees AntriaBio has estimated a forfeiture rate of zero. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Expected volatility 97 - 100 % Risk free interest rate 1.69% - 1.91 % Expected term (years) 7 Dividend yield 0 % AntriaBio computed the fair value of all options granted during the year ended June 30, 2015 using the following assumptions: Expected volatility 90 - 103 % Risk free interest rate 1.31% - 2.38 % Expected term (years) 5-7 Dividend yield 0 % Weighted Weighted Average Number of Average Remaining Options Exercise Price Contractual Life Outstanding, June 30, 2014 4,343,334 $ 3.61 5.6 Granted 4,572,000 $ 2.02 Forfeited (212,916) $ 3.57 Outstanding, June 30, 2015 8,702,418 $ 2.78 7.1 Granted 285,000 $ 1.07 Forfeited (40,000) $ 1.66 Outstanding, June 30, 2016 8,947,418 $ 2.73 6.2 Exercisable at June 30, 2016 4,497,646 $ 3.18 4.9 Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development - compensation and benefits expense of $ 1,218,040 671,958 2,543,797 2,174,870 7,902,071 - Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding, June 30, 2014 11,099,739 $ 2.21 3.6 Warrants issued in private placements 6,040,921 $ 2.50 Warrants issued to placement agent 1,824,489 $ 2.50 Warrants issued for investor relations 111,000 $ 1.63 Warrants cancelled (59,758) $ 2.92 Outstanding, June 30, 2015 19,016,391 $ 2.33 3.0 Warrants issued in stock conversion 5,897,677 $ 1.65 Warrants issued in private placements 3,043,669 $ 1.65 Warrants issued to placement agent 933,639 $ 1.61 Warrants issued for investor relations 103,000 $ 1.60 Warrants cancelled (30,000) $ 3.44 Outstanding, June 30, 2016 28,964,376 $ 2.11 3.1 Year Ended June 30, 2015: 6,040,921 2.50 1,824,489 2.50 105,000 1.65 6,000 1.38 Year ended June 30, 2016: 5,897,677 1.65 3,043,669 1.65 184,490 2.34 327,046 1.32 87,500 2.50 519,093 1.65 9,000 1.38 24,000 1.34 60,000 1.85 10,000 0.96 The warrants exercisable for the 66,667 50,365 30,000 11,955 31,777 4,968,482 3,527,816 2,597,932 1,072,439 1,009,433 595,184 105,000 80,677 6,000 9,006 1,477,287 58,914 92,111 1,418,373 1,498,809 2,217,605 347,202 247,552 309,121 99,650 172,809 124,434 The warrants exercisable for the 5,897,677 3,497,914 3,043,558 1,667,630 1,202,336 The warrants exercisable for 184,490 184,673 327,046 113,521 87,500 65,490 519,093 386,800 The warrants exercisable for the 9,000 11,407 24,000 20,943 60,000 34,122 10,000 6,500 These warrants were valued using the Black-Scholes option pricing model on the date of issuance except for the warrants to purchase 1,518,387 The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions were as follows: Expected volatility 87% - 151 % Risk free interest rate 0.45% - 2.03 % Warrant term (years) 1 - 7.5 Dividend yield 0 % We utilize a Lattice model to determine the fair market value of the warrants to purchase 1,418,373 1,498,809 Expected volatility 90% - 91 % Risk free interest rate 1.89% - 1.98 % Warrant term (years) 7 Dividend yield 0 % We utilize a Lattice model to determine the fair market value of the warrants to purchase 99,650 172,809 Expected volatility 90 % Risk free interest rate 1.71 % Warrant term (years) 7 Dividend yield 0 %

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 12 Income Taxes Year Ended June 30, 2016 2015 Current tax benefit Federal $ - $ - State - - - - Deferred tax benefit Federal 5,065,733 3,774,110 State 339,091 432,092 Change in valuation allowance (5,404,824) (4,206,202) - - Total tax expense $ - $ - As of June 30, 2016 2015 Deferred tax assets Net operating loss carryforward $ 10,602,681 $ 5,170,221 Start-up and organizational expenses 577,110 614,059 Stock-based compensation 4,395,306 3,080,604 Other 265,809 412,783 Total deferred tax assets 15,840,906 9,277,667 Deferred tax liabilities Fixed Assets 1,072,872 83,360 Federal Beneft for state deferred taxex 601,808 432,905 Total deferred tax liabilities 1,674,680 516,265 Valuation allowance (14,166,226) (8,761,402) Net deferred taxes $ - $ - The valuation allowance was established because the Company had not reported earnings in order to support the recognition of the deferred tax asset. The Company has net operating loss carryforwards of approximately $ 27,446,000 2031 6,281,000 34 Year Ended June 30, 2016 2015 Computed "expected" tax expense (benefit) $ (5,078,084) $ (3,863,260) Change in income taxes from: State taxes net of federal benefit (339,091) (432,092) Permanent differences 12,351 229,209 Prior period adjustment - (140,059) Change in valuation allowance (5,404,824) 4,206,202 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 13 Commitments and Contingencies Lease Commitments 27,000 28,939 3 33,325 750,000 187,500 Year Ending June 30, 2017 370,252 2018 381,360 2019 392,855 2020 335,747 $ 1,480,214 In September 2014, the Company entered into an equipment lease for laboratory equipment to be leased for twenty-four months with a bargain purchase option at the end of the lease. The equipment lease has been recorded as a capital lease with monthly payments of $ 8,075 Legal Matters

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis Of Accounting, Policy [Policy Text Block]	Basis of Presentation
Consolidation, Policy [Policy Text Block]
Use Of Estimates, Policy [Policy Text Block]
Risks and Uncertainties [Policy Text Block]
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash –
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	11 7,292
Security Deposit [Policy Text Block]	Deposits
Convertible Notes Payable [Policy Text Block]	Convertible Notes Payable
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs
Selling, General and Administrative Expenses, Policy [Policy Text Block]	General and Administrative Expenses
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows ASC 740 (formerly known as FIN No. 48, Accounting for Uncertainty in Income Taxes An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss)
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) Per Common Share – Although there were common stock equivalents of 33,462,014 21,556,142
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments – Fair Value Measurements and Disclosures ⋅ Level 1: Quoted prices for identical assets and liabilities in active markets; ⋅ Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ⋅ Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, restricted cash, accounts payable, and convertible notes payable approximated fair value as of June 30, 2016 and 2015 due to the relatively short maturity of the respective instruments. The warrant derivative liability recorded as of June 30, 2016 and 2015 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability is a level 3 fair value instrument with the entire change in the balance recorded through earnings. See significant assumptions in Note 11. Balance as of June 30, 2015 $ (31,777) Total unrealized gains (losses): Included in earnings 19,822 Balance as of June 30, 2016 $ (11,955)
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items (Subtopic 225-20) In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes, In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09. Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.
Reclassification, Policy [Policy Text Block]	Reclassifications –

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy: Balance as of June 30, 2015 $ (31,777) Total unrealized gains (losses): Included in earnings 19,822 Balance as of June 30, 2016 $ (11,955)

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	The following is a summary of fixed assets and accumulated depreciation: Useful Life June 30, 2016 June 30, 2015 Furniture and fixtures 5 - 7 years $ 62,730 $ 55,330 Lab equipment 3 - 15 years 3,585,590 889,672 Lab equipment (not yet placed in service) 3 - 15 years 4,025 1,371,440 Leasehold Improvements 3 - 7 years 3,211,575 29,296 Construction in process - - 2,315,803 6,863,920 4,661,541 Less: accumulated depreciation and amortization (879,250) (136,629) $ 5,984,670 $ 4,524,912

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected volatility 97 - 100 % Risk free interest rate 1.69% - 1.91 % Expected term (years) 7 Dividend yield 0 % AntriaBio computed the fair value of all options granted during the year ended June 30, 2015 using the following assumptions: Expected volatility 90 - 103 % Risk free interest rate 1.31% - 2.38 % Expected term (years) 5-7 Dividend yield 0 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock option activity is as follows: Weighted Weighted Average Number of Average Remaining Options Exercise Price Contractual Life Outstanding, June 30, 2014 4,343,334 $ 3.61 5.6 Granted 4,572,000 $ 2.02 Forfeited (212,916) $ 3.57 Outstanding, June 30, 2015 8,702,418 $ 2.78 7.1 Granted 285,000 $ 1.07 Forfeited (40,000) $ 1.66 Outstanding, June 30, 2016 8,947,418 $ 2.73 6.2 Exercisable at June 30, 2016 4,497,646 $ 3.18 4.9
Schedule Of Warrants Issued To Agents Activity [Table Text Block]	Warrants - Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding, June 30, 2014 11,099,739 $ 2.21 3.6 Warrants issued in private placements 6,040,921 $ 2.50 Warrants issued to placement agent 1,824,489 $ 2.50 Warrants issued for investor relations 111,000 $ 1.63 Warrants cancelled (59,758) $ 2.92 Outstanding, June 30, 2015 19,016,391 $ 2.33 3.0 Warrants issued in stock conversion 5,897,677 $ 1.65 Warrants issued in private placements 3,043,669 $ 1.65 Warrants issued to placement agent 933,639 $ 1.61 Warrants issued for investor relations 103,000 $ 1.60 Warrants cancelled (30,000) $ 3.44 Outstanding, June 30, 2016 28,964,376 $ 2.11 3.1
Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	Expected volatility 87% - 151 % Risk free interest rate 0.45% - 2.03 % Warrant term (years) 1 - 7.5 Dividend yield 0 %
Lattice Model Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	Expected volatility 90 % Risk free interest rate 1.71 % Warrant term (years) 7 Dividend yield 0 %
Lattice Model One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	Expected volatility 90% - 91 % Risk free interest rate 1.89% - 1.98 % Warrant term (years) 7 Dividend yield 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Taxing jurisdictions related to income taxes are the Unites States Federal Government, the State of Colorado and the State of California. The provision for income taxes is as follows: Year Ended June 30, 2016 2015 Current tax benefit Federal $ - $ - State - - - - Deferred tax benefit Federal 5,065,733 3,774,110 State 339,091 432,092 Change in valuation allowance (5,404,824) (4,206,202) - - Total tax expense $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred taxes are a result of differences between income tax accounting and GAAP with respect to income and expenses. The following is a summary of the components of deferred taxes recognized in the financial statements as of June 30, 2016 and 2015: As of June 30, 2016 2015 Deferred tax assets Net operating loss carryforward $ 10,602,681 $ 5,170,221 Start-up and organizational expenses 577,110 614,059 Stock-based compensation 4,395,306 3,080,604 Other 265,809 412,783 Total deferred tax assets 15,840,906 9,277,667 Deferred tax liabilities Fixed Assets 1,072,872 83,360 Federal Beneft for state deferred taxex 601,808 432,905 Total deferred tax liabilities 1,674,680 516,265 Valuation allowance (14,166,226) (8,761,402) Net deferred taxes $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate of 34 Year Ended June 30, 2016 2015 Computed "expected" tax expense (benefit) $ (5,078,084) $ (3,863,260) Change in income taxes from: State taxes net of federal benefit (339,091) (432,092) Permanent differences 12,351 229,209 Prior period adjustment - (140,059) Change in valuation allowance (5,404,824) 4,206,202 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending June 30, 2017 370,252 2018 381,360 2019 392,855 2020 335,747 $ 1,480,214

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2016USD ($)
Summary of Significant Accounting Policies [Line Items]
Balance as of June 30, 2015	$ (31,777)
Total unrealized gains (losses):
Included in earnings	19,822
Balance as of June 30, 2016	$ (11,955)

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Income Tax Examination, Likelihood of Unfavorable Settlement	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Two	7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Three	7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Four	7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 7,292
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	33,462,014	21,556,142
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	11 years

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Going Concern [Line Items]
Net Loss	$ (14,935,542)	$ (11,362,364)
Net Cash Used In Operating Activities	(10,488,498)	(7,078,894)
Total Stockholders' Equity	8,772,853	9,053,807	$ 6,406,731
Accumulated deficit	$ (44,044,830)	$ (29,109,288)

Acquisition of Assets (Details

Acquisition of Assets (Details Textual) - USD ($)	Nov. 06, 2014	Jan. 30, 2013
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 400,000
Business Acquisition Purchases Price Allocation Assets Acquired		100,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset	$ 55,000
Maximum [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Current		$ 44,000,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 6,863,920	$ 4,661,541
Less: accumulated depreciation and amortization	(879,250)	(136,629)
Property, Plant and Equipment, Net	5,984,670	4,524,912
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 62,730	55,330
Furniture and fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,585,590	889,672
Lab equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Lab equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Lab equipment (not yet placed in service) [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 4,025	1,371,440
Lab equipment (not yet placed in service) [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Lab equipment (not yet placed in service) [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,211,575	29,296
Leasehold improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 0	$ 2,315,803
Property, Plant and Equipment, Useful Life	0 years

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 743,962	$ 128,870
Property, Plant and Equipment, Gross	6,863,920	4,661,541
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 0	$ 2,315,803

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Related Party Transaction [Line Items]
Consulting expenses			$ 99,000
Forgiveness of accounts payable and accrued expenses - related party		$ 0	$ (132,339)
Minimum Securities Value, Purchase Commitments		$ 8,000,000
Subsequent Event [Member]
Related Party Transaction [Line Items]
Consulting Agreement Fees Per Month	$ 10,350
PH Pharma Co Ltd [Member]
Related Party Transaction [Line Items]
Intellectual Property License Effective Terms		License to become effective, PH must purchase at least $6 million of the Companys common stock in one or more private placement transactions at prices to be negotiated in good faith by the parties based on commercially reasonable terms.
Equity Method Investments		$ 2,000,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended
	Mar. 31, 2014	Jun. 30, 2016	Jun. 30, 2015
Convertible Notes Payable
Convertible Notes Payable [Line Items]
Debt instrument, interest rate, stated percentage		8.00%
Debt conversion, converted instrument, amount	$ 4,275,172
Debt instrument convertible number of common stock	3,111,126
Debt Instrument, Face Amount		$ 60,000	$ 60,000
2013 Notes
Convertible Notes Payable [Line Items]
Debt conversion, converted instrument, amount	$ 2,703,000
Debt instrument convertible number of common stock	2,186,838

Series A Convertible Preferre35

Series A Convertible Preferred Stock (Details Textual) - USD ($)	Apr. 12, 2016	Dec. 10, 2015	Dec. 07, 2015	Mar. 31, 2016	Jun. 30, 2016	Mar. 02, 2016	Jun. 30, 2015
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Shares Authorized					20,000,000		20,000,000
Preferred Stock, Conversion Basis			The Series A Stock had a conversion feature at the option of the holder that could be converted at any time at a conversion rate of $1.95, subject to adjustment, into common stock. The shares also had a mandatory conversion feature at the same conversion rate if one of the following events occurs: 1) Upon vote or consent of 2/3 of the then outstanding Series A Stock; 2) Upon the Companys listing to NASDAQ Stockmarket or the NYSE MKT and the Companys common stock trades for 30 days for at least 155% of the Series A Stock conversion price; or 3) the Company closes an underwritten public offering of at least $15 million in gross proceeds with an offering price of at least 155% of the Series A Stock conversion price. The Series A Stocks conversion price was subject to weighted average anti-dilution protection, as defined, and was subject to adjustments for stock splits, dividends, and similar events.
Preferred Stock, Redemption Price Per Share	$ 1.95
Preferred Stock Shares Issued	512,820				0		0
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 1,000,000
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock [Line Items]
Preferred Stock, Shares Authorized			15,000,000
Preferred Stock, Dividend Rate, Percentage			6.00%
Preferred Stock, Redemption Price Per Share		$ 1.95				$ 1.95
Preferred Stock Shares Issued		1,025,699				1,716,487
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 1,803,548		$ 2,956,975
Preferred Stock, Accretion of Redemption Discount					$ 22,846
Dividends Preferred Stock, Shares					71,708
Conversion of Stock, Shares Converted					3,326,714
Conversion Of Stock, Conversion Price					$ 1.95
Conversion Of Stock, Exchange Shares And Exchange Warrants Issued					5,897,677
Conversion Of Stock, Excess Fair Value Of Securities					$ 5,811,700
Conversion Of Stock, Gain On Conversion Of Stock					$ 2,929,084
Convertible Preferred Stock, Terms of Conversion					Series A stockholder to exchange the Conversion Shares into shares of common stock and related warrants equal to the Series A Preferred Stock purchase price plus accrued dividends at an exchange rate of $1.10 per Exchange Share and related Exchange Warrant.
Series A Convertible Preferred Stock [Member] | Warrant [Member]
Series A Convertible Preferred Stock [Line Items]
Payments of Debt Issuance Costs		90,852		159,311
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Series A Convertible Preferred Stock [Line Items]
Payments of Debt Issuance Costs		$ 105,715		$ 231,214

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 29, 2016	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2014
Class of Stock [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued		$ 5,523,706	$ 6,026,070
Common Stock, Shares Authorized		200,000,000	200,000,000
Common Stock, Par Or Stated Value Per Share		$ 0.001	$ 0.001
Preferred Stock, Shares Authorized		20,000,000	20,000,000
Preferred Stock, Par Or Stated Value Per Share		$ 0.001	$ 0.001
Compensation For Services [Member]
Class of Stock [Line Items]
Common Stock To Be Issued				500,000
Warrant
Class of Stock [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued		$ 500,321
Investor Relations
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other			166,668
Stock Issued During Period, Value, Other			$ 296,669
Private Placement
Class of Stock [Line Items]
Payments of stock issuance costs		$ 553,428	$ 1,071,568
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.65	$ 2.50
Adjustments to Additional Paid in Capital, Warrant Issued			$ 2,072,911
Stock Issued During Period, Shares, Issued for Services			37,838
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs			$ 70,000
Class Of Warrant Or Right Of Warrants Or Rights Expiring Period		60 months	36 months
Issuance Of Common Stock Shares		4,875,020	6,040,921
Proceeds from Issuance of Private Placement		$ 4,800,000	$ 10,100,000
Private Placement | Subsequent Event
Class of Stock [Line Items]
Issuance Of Common Stock Shares	418,182
Proceeds from Issuance of Private Placement	$ 460,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	7 years
Dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.00%	90.00%
Risk free interest rate	1.69%	1.31%
Expected term (years)		5 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	100.00%	103.00%
Risk free interest rate	1.91%	2.38%
Expected term (years)		7 years

Stock-Based Compensation (Det38

Stock-Based Compensation (Details 1) - Stock Option - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Number of Options
Outstanding	8,702,418	4,343,334
Granted	285,000	4,572,000
Forfeited	(40,000)	(212,916)
Outstanding	8,947,418	8,702,418	4,343,334
Exercisable	4,497,646
Weighted Average Exercise Price
Outstanding	$ 2.78	$ 3.61
Granted	1.07	2.02
Forfeited	1.66	3.57
Outstanding	2.73	$ 2.78	$ 3.61
Exercisable	$ 3.18
Weighted Average Remaining Contractual Life
Outstanding	6 years 2 months 12 days	7 years 1 month 6 days	5 years 7 months 6 days
Exercisable	4 years 10 months 24 days

Stock-Based Compensation (Det39

Stock-Based Compensation (Details 2) - Warrant - $ / shares	1 Months Ended	12 Months Ended
	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Number of Warrants - Outstanding		19,016,391	11,099,739
Number of Warrants - issued in stock conversion		5,897,677
Number of Warrants - Warrants issued in private placements		3,043,669	6,040,921
Number of Warrants - Warrants issued to placement agent		933,639	1,824,489
Number of Warrants - Warrants issued for investor relations		103,000	111,000
Number of Warrants - Warrants cancelled	(30,000)	(30,000)	(59,758)
Number of Warrants - Outstanding		28,964,376	19,016,391	11,099,739
Weighted Average Exercise Price - Outstanding		$ 2.33	$ 2.21
Weighted Average Exercise Price - Warrants issued in stock conversion		1.65
Weighted Average Exercise Price - Warrants issued in private placement		1.65	2.5
Weighted Average Exercise Price - Warrants issued to placement agent		1.61	2.5
Weighted Average Exercise Price - Warrants issued for investor relations		1.6	1.63
Weighted Average Exercise Price - Warrants cancelled		3.44	2.92
Weighted Average Exercise Price - Outstanding		$ 2.11	$ 2.33	$ 2.21
Weighted Average Remaining Contractual Life - Outstanding		3 years 1 month 6 days	3 years	3 years 7 months 6 days

Stock-Based Compensation (Det40

Stock-Based Compensation (Details 3)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term (years)	7 years
Dividend yield	0.00%	0.00%
Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.00%	90.00%
Risk free interest rate	1.69%	1.31%
Warrant term (years)		5 years
Minimum | Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	87.00%
Risk free interest rate	0.45%
Warrant term (years)	1 year
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	100.00%	103.00%
Risk free interest rate	1.91%	2.38%
Warrant term (years)		7 years
Maximum | Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	151.00%
Risk free interest rate	2.03%
Warrant term (years)	7 years 6 months

Stock-Based Compensation (Det41

Stock-Based Compensation (Details 4)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term (years)	7 years
Dividend yield	0.00%	0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	100.00%	103.00%
Risk free interest rate	1.91%	2.38%
Warrant term (years)		7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.00%	90.00%
Risk free interest rate	1.69%	1.31%
Warrant term (years)		5 years
Lattice Model One | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	91.00%
Risk free interest rate	1.98%
Lattice Model One | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.00%
Risk free interest rate	1.89%
Lattice Model One | Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term (years)	7 years
Dividend yield	0.00%

Stock-Based Compensation (Det42

Stock-Based Compensation (Details 5)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term (years)	7 years
Dividend yield	0.00%	0.00%
Lattice Model Two [Member] | Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.00%
Risk free interest rate	1.71%
Warrant term (years)	7 years
Dividend yield	0.00%

Stock-Based Compensation (Det43

Stock-Based Compensation (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Dec. 31, 2015	Feb. 23, 2015	Jan. 31, 2013	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Apr. 06, 2015	Mar. 31, 2015	Mar. 26, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation				$ 3,761,837	$ 2,846,828
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options				7,902,071
Fair value of warrants				11,955	31,777
Adjustments to Additional Paid in Capital, Warrant Issued				$ 5,523,706	$ 6,026,070
Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights		58,914
Class of warrant exercisable warrants or rights							247,552
Adjustments to Additional Paid in Capital, Warrant Issued		$ 92,111
Lattice Model Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights								99,650
Warrants to purchase common stock value							$ 309,121
Warrant derivative liability								$ 172,809
Lattice Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				99,650
Warrants to purchase common stock value				$ 172,809
Lattice Model One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				1,418,373
Warrant derivative liability				$ 1,498,809
2014 Stock and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized									3,750,000
Two Consultants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross					8,334
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price					$ 4.50
Employees and Directors | General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation				2,543,797	$ 2,174,870
Employees and Directors | Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation				$ 1,218,040	$ 671,958
Employees and Directors | 2014 Stock and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross					460,000
Share based compensation arrangement by share based payment award options shares purchased vested monthly term		4 years
Employees and Directors | 2014 Stock and Incentive Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price					$ 1.29
Employees and Directors | 2014 Stock and Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price					$ 3.44
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross				285,000	4,572,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price				$ 1.07	$ 2.02
Employee Stock Option | Employees and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, options, grants in period, gross			1,500,000		4,112,000	2,835,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price			$ 4.50
Share-based compensation arrangement by share-based payment award, number of shares authorized		6,850,000
Employee Stock Option | Employees and Directors | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 1
Employee Stock Option | Employees and Directors | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 2.06
Additional Paid-in Capital and Professional Fee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock value				$ 80,677
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued				$ 500,321
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants cancelled In Period	30,000			30,000	59,758
Warrant | Lattice Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				1,518,387
Warrant | Additional Paid-in Capital and Professional Fee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock value				$ 9,006
Warrant One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				5,897,677	6,040,921
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.65	$ 2.50
Class of warrant exercisable warrants or rights				5,897,677
Warrants to purchase common stock value				$ 3,497,914
Warrant Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				3,043,669	1,824,489
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.65	$ 2.50
Class of warrant exercisable warrants or rights				3,043,558
Warrants to purchase common stock value				$ 1,667,630
Adjustments to Additional Paid in Capital, Warrant Issued				$ 1,202,336
Warrant Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				184,490	105,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.34	$ 1.65
Class of warrant exercisable warrants or rights				184,490
Warrants to purchase common stock value				$ 184,673
Warrant Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				327,046	6,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.32	$ 1.38
Class of warrant exercisable warrants or rights				327,046
Warrants to purchase common stock value				$ 113,521
Warrant Five
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				87,500
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.50
Class of warrant exercisable warrants or rights				87,500
Warrants to purchase common stock value				$ 65,490
Warrant Six
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				519,093
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.65
Class of warrant exercisable warrants or rights				519,093
Warrants to purchase common stock value				$ 386,800
Warrant Seven
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				9,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.38
Class of warrant exercisable warrants or rights				9,000
Warrants to purchase common stock value				$ 11,407
Warrant Eight
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				24,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.34
Class of warrant exercisable warrants or rights				24,000
Warrants to purchase common stock value				$ 20,943
Warrant Nine
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				60,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.85
Class of warrant exercisable warrants or rights				60,000
Warrants to purchase common stock value				$ 34,122
Warrant Ten
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				10,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.96
Class of warrant exercisable warrants or rights				10,000
Warrants to purchase common stock value				$ 6,500
Warrant Thirteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant exercisable warrants or rights				66,667
Adjustments to Additional Paid in Capital, Warrant Issued				$ 50,365
Warrant Fourteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant exercisable warrants or rights				4,968,482
Warrants to purchase common stock value				$ 3,527,816
Adjustments to Additional Paid in Capital, Warrant Issued				$ 2,597,932
Warrant Fifteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant exercisable warrants or rights				1,477,287
Warrant Sixteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				1,072,439
Class of warrant exercisable warrants or rights				6,000
Warrants to purchase common stock value				$ 1,009,433
Adjustments to Additional Paid in Capital, Warrant Issued				$ 595,184
Warrant Eighteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, number of securities called by warrants or rights				105,000
Warrant Eighteen | Lattice Model [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant derivative liability				$ 1,498,809
Warrant Eighteen | Derivative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase common stock value		$ 2,217,605					$ 124,434
Warrant Ninteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant exercisable warrants or rights				347,202

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Current tax benefit
Federal	$ 0	$ 0
State	0	0
Current Income Tax Expense (Benefit)	0	0
Deferred tax benefit
Federal	5,065,733	3,774,110
State	339,091	432,092
Change in valuation allowance	(5,404,824)	(4,206,202)
Deferred Income Tax Expense (Benefit)	0	0
Total tax expense	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Deferred tax assets
Net operating loss carryforward	$ 10,602,681	$ 5,170,221
Start-up and organizational expenses	577,110	614,059
Stock-based compensation	4,395,306	3,080,604
Other	265,809	412,783
Total deferred tax assets	15,840,906	9,277,667
Deferred tax liabilities
Fixed Assets	1,072,872	83,360
Federal Beneft for state deferred taxex	601,808	432,905
Total deferred tax liabilities	1,674,680	516,265
Valuation allowance	(14,166,226)	(8,761,402)
Net deferred taxes	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Computed "expected" tax expense (benefit)	$ (5,078,084)	$ (3,863,260)
Change in income taxes from:
State taxes net of federal benefit	(339,091)	(432,092)
Permanent differences	12,351	229,209
Prior period adjustment	0	(140,059)
Change in valuation allowance	5,404,824	4,206,202
Income Tax Expense (Benefit)	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual)	12 Months Ended
	Jun. 30, 2016USD ($)
Operating Loss Carryforwards	$ 6,281,000
Operating Loss Carry forwards Expiration Year	2,031
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Operating Loss Carryforwards, Valuation Allowance	$ 27,446,000

Commitments and Contingencies48

Commitments and Contingencies (Details)	Jun. 30, 2016USD ($)
Operating Leased Assets [Line Items]
2,017	$ 370,252
2,018	381,360
2,019	392,855
2,020	335,747
Operating Leases, Future Minimum Payments Due	$ 1,480,214

Commitments and Contingencies49

Commitments and Contingencies (Details Textual)	1 Months Ended	12 Months Ended
	May 31, 2014USD ($)ft²	Jun. 30, 2016USD ($)	Sep. 30, 2014USD ($)
Commitments And Contingencies [Line Items]
Operating Leases, Rent Expense	$ 28,939
Payments Of Monthly Lease Adjusted Annually Percentage	3.00%
Adjusted Triple Net Expense Of Lease Payments	$ 33,325
Area of Land | ft²	27,000
Security Deposit	$ 750,000
Proceeds from Other Deposits		$ 187,500
Capital Lease Obligations
Commitments And Contingencies [Line Items]
Capital Lease Obligations			$ 8,075